We can find abnormal HER3 expression in a variety of cancers, including breast cancer, prostate cancer, gastric cancer, and NSCLC, which may be associated with progression or poor prognosis in these cancers (Kawakami and Yonesaka, 2016; Scharpenseel et al., 2019; Gil et al., 2021). Here, ERBB3 is linked to cancer.